News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

First-line Bevacizumab Contributes to Survival Improvement in Glioblastoma Patients Complementary to Temozolomide

Al's Comment:

 This is a controversial area.  Some prior studies on GBM said there was an improvement in progression free survival with Bevacizumab (Avastin) but no improvement in overall survival.  This study says there is an improvement with adding Avastin to the standard Temodar, and that benefit persists even if the MGMT is unmethylated.  This opens another option for unmethylated MGMT patients.  However, I would like to see more data as there are too many conflicting reports.


Posted on: 03/14/2020

First-line Bevacizumab Contributes to Survival Improvement in Glioblastoma Patients Complementary to Temozolomide

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740